ARS Pharmaceuticals, Inc. (SPRY) Operating cash flow 2020–2025
ARS Pharmaceuticals, Inc. (SPRY) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$170.9MFY2025 · since FY2020: -$31.2M → -$170.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$170.9M | -1361.2% |
| FY2024 | $13.5M | +122.9% |
| FY2023 | -$59.3M | -47.9% |
| FY2022 | -$40.1M | -128.2% |
| FY2021 | -$17.6M | +43.7% |
| FY2020 | -$31.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →